Skip to content

US · KRMD · MEDICAL - INSTRUMENTS & SUPPLIES

KORU Medical Systems, Inc. (KRMD) intrinsic value and stock valuation

$3.19as of 2026-11-21 · Mkt cap 189.7M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

KORU Medical Systems, Inc. DCF and intrinsic value

InvestorsCraft values KRMD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KRMD’s statements →

KORU Medical Systems, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Mahwah, NY 07430 korumedical.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$41.1M+11.2% 5y CAGRd
20112025
Net income
-$-2.64M
20112025
Free cash flow
-$-470K
20112025
Total equity
$17.1M-14% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$41.1M$33.7M$28.5M$27.9M$23.5M
Operating income-$-2.97M-$-6.45M-$-10.27M-$-10.78M-$-7.03M
Net income-$-2.64M-$-6.07M-$-13.74M-$-8.66M-$-4.56M
EPSd-$-57.16K-$-132.53K-$-301.32K-$-192.44K-$-102.73K
Operating cash flow$460K-$-320K-$-4.89M-$-5.4M-$-4.32M
Capital expenditure-$-930K-$-1.3M-$-810K-$-2.8M-$-380K
Free cash flow-$-470K-$-1.62M-$-5.71M-$-8.21M-$-4.69M
Total assets$28.2M$27.2M$28.5M$42.3M$41.3M
Total debt$3.5M$3.99M$4.45M$4.93M$600K
Net debt-$-5.38M-$-5.59M-$-7.04M-$-12.48M-$-24.73M
Total equity$17.1M$16.8M$20.4M$31.3M$36.5M
Cash and short-term investments$8.87M$9.58M$11.5M$17.4M$25.3M
Income statement
20252024202320222021
Revenue$41.1M$33.7M$28.5M$27.9M$23.5M
Cost of revenue$15.5M$12.3M$11.8M$12.5M$9.72M
Gross profit$25.6M$21.3M$16.7M$15.4M$13.8M
Research and development expenses$4.39M$5.26M$5.74M$4.96M$2.47M
Selling, general and administrative expenses$23.4M$0.00$0.00$0.00$0.00
Other expenses$810K$22.5M$21.2M$21.2M$18.3M
Operating expenses$28.6M$27.8M$27M$26.2M$20.8M
Cost and expenses$44.1M$40.1M$38.8M$38.7M$30.5M
Interest income$290K$440K$560K$150K$10K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$810K$770K$870K$590K$460K
Ebitda-$-1.81M-$-5.29M-$-8.9M-$-10.09M-$-5.9M
Operating income-$-2.97M-$-6.45M-$-10.27M-$-10.78M-$-7.03M
Total other income/expenses, net$360K$380K$500K$110K$670K
Income before tax-$-2.62M-$-6.06M-$-9.77M-$-10.68M-$-6.36M
Income tax expense$20K$0.00$3.97M-$-2.01M-$-1.8M
Net income-$-2.64M-$-6.07M-$-13.74M-$-8.66M-$-4.56M
Weighted average shares outstanding$46.2M$45.8M$45.6M$45M$44.4M
Weighted average diluted shares outstanding$46.2M$45.8M$45.6M$45M$44.4M
Balance sheet
20252024202320222021
Cash and short-term investments$8.87M$9.58M$11.5M$17.4M$25.3M
Net receivables$6.53M$6M$4.05M$3.56M$3.59M
Inventory$3.68M$2.8M$3.48M$6.4M$6.11M
Total current assets$20M$19.1M$20.3M$29.8M$37.3M
Property, plant and equipment, net$7.43M$7.26M$7.35M$7.67M$1.2M
Goodwill and intangible assets$680K$730K$750K$790K$810K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$8.21M$8.09M$8.21M$12.5M$3.97M
Total assets$28.2M$27.2M$28.5M$42.3M$41.3M
Accounts payable$2.27M$1.65M$980K$2.39M$1.23M
Short-term debt$540K$790K$790K$880K$600K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.19M$7.2M$4.45M$6.96M$4.79M
Long-term debt$2.96M$3.2M$3.65M$4.05M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.96M$3.2M$3.65M$4.05M$0.00
Capital lease obligations$0.00$3.72M$4.13M$4.49M$100K
Total liabilities$11.2M$10.4M$8.11M$11M$4.79M
Common stock$500K$490K$490K$490K$480K
Retained earnings-$-32.02M-$-29.38M-$-23.31M-$-9.57M-$-910K
Accumulated other comprehensive income (loss)-$0.00$0.00$0.00$0.00$0.00
Total equity$17.1M$16.8M$20.4M$31.3M$36.5M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$3.5M$3.99M$4.45M$4.93M$600K
Net debt-$-5.38M-$-5.59M-$-7.04M-$-12.48M-$-24.73M
Cash flow statement
20252024202320222021
Net income-$-2.64M-$-6.07M-$-13.74M-$-8.66M-$-4.56M
Depreciation and amortization$810K$890K$870K$590K$460K
Stock-based compensation$2.71M$2.62M$2.77M$3.08M$2.71M
Change in working capital-$-320K$1.97M$1.2M$1.4M-$-1.11M
Accounts receivable-$-490K-$-1.68M$460K-$-220K-$-1.74M
Inventory-$-870K$680K$2.92M-$-300K$720K
Accounts payable$620K$670K-$-1.42M$1.16M$600K
Net cash provided by operating activities$460K-$-320K-$-4.89M-$-5.4M-$-4.32M
Investments in property, plant and equipment-$-930K-$-1.3M-$-780K-$-2.76M-$-350K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-950K-$-1.33M-$-810K-$-2.8M-$-370K
Common stock issued$190K$0.00$0.00$410K$2.2M
Common stock repurchased$0.00-$-100K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-220K-$-250K-$-220K$280K$2.71M
Net change in cash-$-710K-$-1.9M-$-5.93M-$-7.93M-$-1.98M
Cash at end of period$8.87M$9.58M$11.5M$17.4M$25.3M
Operating cash flow$460K-$-320K-$-4.89M-$-5.4M-$-4.32M
Capital expenditure-$-930K-$-1.3M-$-810K-$-2.8M-$-380K
Free cash flow-$-470K-$-1.62M-$-5.71M-$-8.21M-$-4.69M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About KORU Medical Systems, Inc.

        KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's primary offerings revolve around mechanical infusion solutions, notably their FREEDOM infusion systems. These comprehensive systems encompass components such as the FREEDOM60 and FreedomEdge syringe drivers, alongside specialized HIgH-Flo subcutaneous safety needle sets and precision flow rate tubing. Beyond their product range, KORU Medical also supplies educational content and training materials to healthcare professionals, patients, and patient advocates. The distribution of their products is managed through a combination of direct sales efforts, partnerships with medical device distributors, and online channels. Established in 1980, the firm's corporate headquarters are situated in Chester, New York.

        CEO
        Adam Kalbermatten
        Employees
        73
        Beta
        0.41

        Explore

        Frequently asked questions

        What is the intrinsic value of KORU Medical Systems, Inc. (KRMD)?

        InvestorsCraft does not currently publish an intrinsic value for KRMD. How the IC value is calculated.

        Is KRMD undervalued?

        InvestorsCraft does not publish an undervaluation signal for KRMD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.